Endometriosis and adenomyosis: some aspects of medical (endocrine) treatment (part 1)

AD Ebert
In: Siberian Medical Review · 2022 · vol. 6 , pp. 111–116 · doi:10.20333/25000136-2022-6-111-116 · W4312904334
article OA: diamond CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This review analyzes literature on risk factors and pathogenesis of endometriosis and adenomyosis, focusing on cytokines and steroidogenesis, and highlights hormonal drugs, especially progestogens, as first-line treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Th e article presents analysis of relevant literature on risk factors and pathogenesis of endometriosis and adenomyosis. Despite of numerous studies, it has not been possible so far to formulate a unifi ed concept of the pathogenesis and etiology of endometriosis and adenomyosis. We discuss the role of cytokines, including chemokines, prostaglandins and matrix metalloproteinases, as well as disorders of steroid genesis in the pathogenesis of endometriosis. It has been shown that the main therapeutical approach for patients with endometriosis is the diff erentiated use of modern hormonal drugs, which depends on age and reproductive plans. According to the more recent European guidelines, progestogens are the drugs of the fi rst line

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (22)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK